✦ LIBER ✦

Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fondaparinux versus Enoxaparin in non–ST

✍ Mark J. Sculpher; Greta Lozano-Ortega; Jennifer Sambrook; Stephen Palmer; Orges 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Design and rationale of CURRENT-OASIS 7:

✍ Shamir R. Mehta; Jean-Pierre Bassand; Susan Chrolavicius; Rafael Diaz; Keith A.A 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 361 KB

The Early Glycoprotein IIb/IIIa Inhibiti

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Study design and rationale of a comparis

✍ Chee Tang Chin; Matthew T. Roe; Keith A.A. Fox; Dorairaj Prabhakaran; Debra A. M 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 311 KB